Big Bucks will be needed for ENZC to continue to GREATNESS:
Technology and processes for accelerating the production of monoclonal antibodies that target critical virus sites identified by the Company using its A.I. platform. The Company has identified critical conserved target sites on 20 viruses, including human and animal viruses, and is engaging with biotech companies having expertise in accelerating the production of such antibodies.
Related, synergistic or complimentary therapeutics and business structure for the purpose of potential combination with other biotech entities.
Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise target sites on both the Coronavirus and HIV viruses which are then used in the Company’s Texas lab against which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.
Specialized cell sorting technology that is complementary to the process used in the Company’s lab to accelerate production of mAbs for advancing production.
Expertise in hybridoma production techniques for producing mAbs using hybridoma methodologies complementary to the process used in the Company's lab.
Animal trials centers, both in the U.S. and abroad, for the preparation of animal trials.
Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the substantial funds needed for the production of the recombinant mAbs necessary for future trials and for conducting animal trials.
As to each of these entities and those with whom the Company currently works on an ongoing basis, the Company has entered into NDAs (Nondisclosure Agreements) necessary to preserve and protect the Company plans and intellectual property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company and its partners. Maintenance of strict confidentiality is essential to preserving intellectual property rights (patent rights) which are now being sought and will be sought in the future. Premature disclosure of information can bar the right to seek patent protection at a later date. The Company is not able to share specific details regarding arrangements regarding these NDAs.
The term of these NDAs is not time limited. The term extends until the later of five (5) years from the Effective Date or "until such time as the proprietary information is publicly known and made generally available". This provision is necessary because under Patent Laws an issued patent may be invalidated where the patent is filed subsequent to public disclosure of the invention claimed. In view of this limitation, the Company makes no public disclosure of information subject to NDAs and inventions covered by them. Additionally, certain technical information shared with companies with whom the Company has entered into an NDA may not be included in a patent application, but rather the subject technical information is maintained as Company confidential ("secret") indefinitely. Also, in these Agreements, the parties generally agree not to reveal the names of the contracting parties for a specified period.
The Company is very confident in its Artificial Intelligence empowered Intellectual Property Portfolio. It has allowed the Company to claim exclusive rights on an international stage covering critical target sites on numerous human and animal viruses. This places the Company on an equal level with the largest biotech companies in that the Company is the first to identify and patent critical sites on many human and animal viruses. This same technology and strategy are being implemented by the Company on new viruses, human or animal.
The Company identified the conserved sites on the Monkeypox Virus even before the World Health Organization declared it a global health emergency last week.
Funding and audit being addressed:
Company Programs Funding
Given the large number of therapeutics being advanced by Enzolytics, the Company is focused on raising the necessary funds for the production and sale in the U.S. and abroad of IPF Immune™, final development of its anti-HIV ITV-1 therapeutic, accelerating the development of multiple monoclonal antibodies for human therapy, and production of animal monoclonal antibodies. The Company’s audit is being finalized, and the Company fully expects to be able to acquire the funding necessary to complete its multiple programs.
